Literature DB >> 33027809

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Carsten U Niemann1, Mark-David Levin2, Julie Dubois3, Sabina Kersting4, Lisbeth Enggaard5, Gerrit J Veldhuis6, Rogier Mous7, Clemens H M Mellink8, Johan A Dobber9, Christian B Poulsen10, Henrik Frederiksen11, Ann Janssens12, Ida Schjødt1, Ellen C Dompeling13, Juha Ranti14, Mattias Mattsson15, Mar Bellido16, Hoa T T Tran17, Kazem Nasserinejad18, Arnon P Kater3.   

Abstract

Entities:  

Year:  2021        PMID： 33027809     DOI： 10.1182/blood.2020008608

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.

Authors:  Lori A Leslie; Anthony R Mato; Lindsey E Roeker; Tatyana A Feldman; Jacob D Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D Zelenetz; Lorenzo Falchi; Jae H Park; David J Straus; Camila Pena Velasquez; Sonia Lebowitz; Yehudit Fox; Kristen Battiato; Carissa Laudati; Meghan C Thompson; Elizabeth McCarthy; Sabrina Kdiry; Rosalba Martignetti; Teja Turpuseema; Michelle Purdom; Dana Paskalis; Hari P Miskin; Peter Sportelli
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

3.  A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy.

Authors:  Renfang Zhang; Jianjun Sun
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

4.  Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.

Authors:  Arnon P Kater; Erik Slinger; Gaspard Cretenet; Anne W Martens; Sriram Balasubramanian; Joel D Leverson; Eric Eldering
Journal:  Blood Adv       Date:  2021-12-14

Review 5.  Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.

Authors:  Xiao Tang; Wenrong Zou; Peng Peng; Yanglu Bai
Journal:  Clin Exp Med       Date:  2021-07-05       Impact factor: 3.984

6.  Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.

Authors:  David E Spaner; Yuxuan Luo; Guizhei Wang; Jennifer Gallagher; Hubert Tsui; Yonghong Shi
Journal:  Cancer Med       Date:  2021-11-17       Impact factor: 4.452

Review 7.  Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.

Authors:  Jing Zhang; Xueying Lu; Jianyong Li; Yi Miao
Journal:  Biomark Res       Date:  2022-04-04

Review 8.  Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.

Authors:  Thomas E Lew; Mary Ann Anderson; John F Seymour
Journal:  Cancer Drug Resist       Date:  2020-05-23

Review 9.  Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.

Authors:  Yvonne J Thus; Eric Eldering; Arnon P Kater; Marcel Spaargaren
Journal:  Leukemia       Date:  2022-06-20       Impact factor: 12.883

Review 10.  Targeting the tumor microenvironment in chronic lymphocytic leukemia.

Authors:  Rebecka Svanberg; Sine Janum; Piers E M Patten; Alan G Ramsay; Carsten U Niemann
Journal:  Haematologica       Date:  2021-09-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.